JP2019528082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528082A5 JP2019528082A5 JP2019517135A JP2019517135A JP2019528082A5 JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5 JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody
- fusion protein
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088589A JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610404956 | 2016-06-08 | ||
| CN201610404956.7 | 2016-06-08 | ||
| PCT/CN2017/087620 WO2017211321A1 (zh) | 2016-06-08 | 2017-06-08 | 增强激动型抗体活性的抗体重链恒定区序列 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088589A Division JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528082A JP2019528082A (ja) | 2019-10-10 |
| JP2019528082A5 true JP2019528082A5 (https=) | 2019-11-21 |
Family
ID=60578403
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517135A Pending JP2019528082A (ja) | 2016-06-08 | 2017-06-08 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2021088589A Pending JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A Active JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088589A Pending JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A Active JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12145993B2 (https=) |
| EP (1) | EP3470424B1 (https=) |
| JP (3) | JP2019528082A (https=) |
| CN (2) | CN107474136B (https=) |
| WO (1) | WO2017211321A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102669985B1 (ko) * | 2015-06-30 | 2024-05-29 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | Btla 융합 단백질 작용제 및 이의 용도 |
| EP3470424B1 (en) * | 2016-06-08 | 2025-04-23 | Shanghai Jiao Tong University School of Medicine | Sequence of antibody heavy chain constant region for enhancing agonist antibody activity |
| CN117924477A (zh) * | 2017-12-19 | 2024-04-26 | 洛克菲勒大学 | 具有改进的效应子功能的人IgG Fc结构域变体 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| CN111788227B (zh) * | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| EP3887397A1 (en) * | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥（蘇州）有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
| US12365740B2 (en) * | 2019-04-10 | 2025-07-22 | Nankai University | Anti-CD40 antibodies and uses thereof |
| CN110981958B (zh) * | 2019-08-23 | 2020-10-20 | 四川大学华西医院 | 一种pd-l1抗体 |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| EP4071167A4 (en) * | 2019-12-03 | 2024-03-06 | Shanghai Jiao Tong University School of Medicine | ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY |
| CN110862455B (zh) * | 2019-12-03 | 2021-12-21 | 源道隆（苏州）医学科技有限公司 | 可结合cd47的多肽及其应用 |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CN114591428B (zh) * | 2020-12-04 | 2024-05-28 | 上海交通大学医学院 | 抗Dsg1抗体及其应用 |
| KR102671409B1 (ko) * | 2021-03-02 | 2024-05-31 | 진화섭 | Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| KR20250108092A (ko) * | 2024-01-02 | 2025-07-15 | 젬파마테크 컴퍼니 리미티드 | 인간화 항체를 생성하는 동물 모델 및 그 제작 방법 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| GEP20105110B (en) * | 2004-08-03 | 2010-11-10 | Transtech Pharma Inc | Rage fusion proteins and their use |
| US20070128193A1 (en) * | 2004-12-22 | 2007-06-07 | O'neil Karyn T | GLP-1 agonists, compositions, methods and uses |
| EA200801174A1 (ru) * | 2005-10-24 | 2009-02-27 | Сентокор, Инк. | Антитела-миметики glp-2, полипептиды, композиции, способы и применения |
| ES2829423T3 (es) * | 2009-04-20 | 2021-05-31 | Kyowa Kirin Co Ltd | Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| MX352889B (es) * | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| EP3738980A1 (en) | 2012-02-24 | 2020-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib |
| EP2847368B1 (en) * | 2012-05-11 | 2020-08-19 | Merck Sharp & Dohme Corp. | Surface anchored light chain bait antibody display system |
| SG10201709559PA (en) * | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN106414494B (zh) * | 2013-11-12 | 2020-09-18 | Ogd2药物 | 具有促凋亡活性的人IgG1衍生的抗体 |
| HUE045065T2 (hu) * | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| CA2945882A1 (en) * | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| US20170196971A1 (en) * | 2014-06-05 | 2017-07-13 | The Board Of Trustees Of The University Of Arkansas | Antibody guided vaccines and methods of use for generation of rapid mature immune responses |
| JP6668345B2 (ja) * | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| AU2016356780A1 (en) * | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| EP3470424B1 (en) * | 2016-06-08 | 2025-04-23 | Shanghai Jiao Tong University School of Medicine | Sequence of antibody heavy chain constant region for enhancing agonist antibody activity |
| CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| EP4071167A4 (en) * | 2019-12-03 | 2024-03-06 | Shanghai Jiao Tong University School of Medicine | ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY |
| KR20230005907A (ko) * | 2020-05-01 | 2023-01-10 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 항-dectin-2 항체 |
| CN114106174A (zh) * | 2020-08-27 | 2022-03-01 | 苏州景涞医疗科技有限公司 | 低毒性抗ox40抗体、其药物组合物及应用 |
-
2017
- 2017-06-08 EP EP17809760.6A patent/EP3470424B1/en active Active
- 2017-06-08 WO PCT/CN2017/087620 patent/WO2017211321A1/zh not_active Ceased
- 2017-06-08 CN CN201710429281.6A patent/CN107474136B/zh active Active
- 2017-06-08 JP JP2019517135A patent/JP2019528082A/ja active Pending
- 2017-06-08 CN CN202210729123.3A patent/CN115304669A/zh active Pending
- 2017-06-08 US US16/308,156 patent/US12145993B2/en active Active
-
2021
- 2021-05-26 JP JP2021088589A patent/JP2021143186A/ja active Pending
-
2024
- 2024-05-29 JP JP2024087108A patent/JP7809372B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528082A5 (https=) | ||
| JP7809372B2 (ja) | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| JP2020530289A5 (https=) | ||
| JP2020521452A (ja) | 標的化免疫寛容 | |
| CA3174097A1 (en) | T-cell modulatory polypeptides with conjugation sites and methods of use thereof | |
| JP2018512430A5 (https=) | ||
| JP2023541771A (ja) | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 | |
| JP2017533207A5 (https=) | ||
| CN121779568A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| JP2023550419A5 (https=) | ||
| CA3058262A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| JP2023515196A (ja) | 脂肪酸分子とコンジュゲートされた抗体及びその使用 | |
| CN115515981A (zh) | 抗肿瘤相关抗原抗体及其用途 | |
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| AU2023234457A1 (en) | Anti-mesothelin antibodies and uses thereof | |
| AU2023218343A1 (en) | Anti-il13ra2 antibodies and uses thereof | |
| KR20250102074A (ko) | 항-5t4 항체 및 이의 용도 | |
| CN120187757A (zh) | 抗EGFRvIII抗体及其用途 | |
| WO2024182475A2 (en) | Anti-ror2 antibodies and uses thereof | |
| WO2024076864A2 (en) | Anti-ror1 antibodies and uses thereof | |
| WO2025147472A1 (en) | Anti-611-ctf p95her2 antibodies and uses thereof | |
| HK40127603A (zh) | 抗egfrviii抗体及其用途 |